A Direct Comparison of Intravenous Enoxaparin With Unfractionated Heparin in Primary Percutaneous Coronary Intervention (from the ATOLL Trial)
Authors:
- Kurt HuberKHKurt Huber
- Marc CohenMCMarc Cohen
- Uwe ZeymerUZUwe Zeymer
- Patrick GoldsteinPGPatrick Goldstein
- Charles PollackCPCharles Pollack
- Johanne SilvainJSJohanne Silvain
- Patrick HenryPHPatrick Henry
- Olivier VarenneOVOlivier Varenne
- Didier CarriéDCDidier Carrié
- Pierre CostePCPierre Coste
- Michael AngioiMAMichael Angioi
- 1 November 2013
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (9) , 1367-1372
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialThe Lancet, 2011
- Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of CardiologyEuropean Heart Journal, 2011
- A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY TrialJACC, 2006
- Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary InterventionNew England Journal of Medicine, 2006
- Comparison of Fondaparinux and Enoxaparin in Acute Coronary SyndromesNew England Journal of Medicine, 2006
- Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized TrialJAMA, 2006
- Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and AspirinA Randomized Controlled TrialJAMA, 2004
- Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor EptifibatideCirculation, 2003
- Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial InfarctionCirculation, 1999
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997